title: Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
abstract: Conventional clinical protocols specify that women initiate depot medroxyprogesterone acetate (DMPA) within 7 days of the onset of menses, and product labeling specifies initiation within 5 days. Women outside of this window should wait until next menses to begin, often leaving them with inadequate interim contraceptive protection. An alternative is for women to initiate monthly hormonal contraception immediately, as a bridge to DMPA, with a scheduled follow-up appointment about 4 weeks later. We evaluated bridge preferences and DMPA initiation among 150 women requesting DMPA who were ineligible for their first injection at the time of clinic visit due to menstrual cycle day. Ninety-eight percent (n = 147) rejected the standard protocol of waiting with condoms or abstinence in favor of a hormonal bridge method. Ninety-seven percent follow-up (n = 146) showed that 86% were satisfied with their bridge method. There were no posttreatment pregnancies, and 55% (n = 81) of participants had initiated DMPA or another long-term contraceptive within 4 weeks of their initial clinic presentation.
authors.affiliation: Women's Health Research Unit, School of Public Health and Family Medicine, University of Cape Town, South Africa.
authors.forename: Chelsea
authors.initials: C
authors.lastname: Morroni
authors.forename: Morgan
authors.initials: M
authors.lastname: Grams
authors.forename: Lorraine
authors.initials: L
authors.lastname: Tiezzi
authors.forename: Carolyn
authors.initials: C
authors.lastname: Westhoff
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D007407:Interviews as Topic; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008598:Menstruation; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate